Ethical Considerations on Clinical Transformation of MSC-Exo in Tumor Therapy
10.12026/j.issn.1001-8565.2023.10.07
- VernacularTitle:MSC-Exo在肿瘤治疗临床转化中的伦理学思考
- Author:
Xiaoyan FAN
1
;
Wenbing MA
2
;
Xiao MA
3
;
Jipeng LI
1
,
4
Author Information
1. Department of Experimental Surgery, the First Affiliated Hospital of Air Force Medical University, Xi’an 710032, China
2. Clinical Pharmacy, Department of Pharmacy, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
3. School of Basic Medicine, Air Force Medical University, Xi’an 710032, China
4. Department of Gastroenterology Surgery, the First Affiliated Hospital of Air Force Medical University, Xi’an 710032, China
- Publication Type:Journal Article
- Keywords:
MSC-Exo;
Tumor Therapy;
Clinical Transformation;
Tumor Patients
- From:
Chinese Medical Ethics
2023;36(10):1103-1109
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, basic scientific research and clinical studies on mesenchymal stem cell-derived exosome (MSC-Exo) have developed rapidly. MSC-Exo has shown good anti-tumor effects in preclinical and clinical studies. However, due to its diverse sources and functions, MSC-Exo therapy still faces many ethical issues in clinical conversion and application, including the unclear tumor types and mechanisms of action applicable to MSC-Exo, the risk/benefit issues in the process of clinical research, the lack of safety/effectiveness evaluation standards, lax access standards, and the incomplete regulatory systems. The technical guidelines and regulatory policies related to the clinical transformation and application of stem cell therapy are constantly improving. Therefore, to effectively avoid ethical risks, regulate the research and treatment related to the clinical transformation and application of MSC-Exo therapy, and improve the safety and efficacy of MSC-Exo therapy in tumor therapy, it is proposed to deepen clinical research on the relationship between MSC-Exo and tumor regulation, strengthen the risk/benefit analysis, supervise and improve the professional quality of researcher, deeply root in the principle of subjects not to be harmed, construct and perfect the relevant regulatory system, and improve the reviewing ability of the ethics committee, so as to promote the rapid clinical transformation of MSC-Exo and bring good news to cancer patients.
